Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A comparative analysis of cytochrome P450 activities in paired liver and small intestinal samples from patients with obesity.

Krogstad V, Peric A, Robertsen I, Kringen MK, Wegler C, Angeles PC, Hjelmesaeth J, Karlsson C, Andersson S, Artursson P, Asberg A, Andersson TB, Christensen H.

Drug Metab Dispos. 2019 Nov 4. pii: dmd.119.087940. doi: 10.1124/dmd.119.087940. [Epub ahead of print]

2.

Tacrolimus area under the concentration versus time curve monitoring, using home-based volumetric absorptive capillary microsampling.

Gustavsen MT, Midtvedt K, Vethe NT, Robertsen I, Bergan S, Åsberg A.

Ther Drug Monit. 2019 Aug 30. doi: 10.1097/FTD.0000000000000697. [Epub ahead of print]

PMID:
31479042
3.

The influence of bariatric surgery on oral drug bioavailability in patients with obesity: A systematic review.

Angeles PC, Robertsen I, Seeberg LT, Krogstad V, Skattebu J, Sandbu R, Åsberg A, Hjelmesaeth J.

Obes Rev. 2019 Sep;20(9):1299-1311. doi: 10.1111/obr.12869. Epub 2019 Jun 24. Review.

PMID:
31232513
4.

Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?

Robertsen I, Woillard JB, Åsberg A.

Br J Clin Pharmacol. 2019 May 29. doi: 10.1111/bcp.13984. [Epub ahead of print] No abstract available.

PMID:
31144343
5.

Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus.

Halden TAS, Kvitne KE, Midtvedt K, Rajakumar L, Robertsen I, Brox J, Bollerslev J, Hartmann A, Åsberg A, Jenssen T.

Diabetes Care. 2019 Jun;42(6):1067-1074. doi: 10.2337/dc19-0093. Epub 2019 Mar 12.

PMID:
30862658
6.

High tacrolimus clearance - a risk factor for development of interstitial fibrosis and tubular atrophy in the transplanted kidney: a retrospective single-center cohort study.

Egeland EJ, Reisaeter AV, Robertsen I, Midtvedt K, Strøm EH, Holdaas H, Hartmann A, Åsberg A.

Transpl Int. 2019 Mar;32(3):257-269. doi: 10.1111/tri.13356. Epub 2018 Oct 15.

PMID:
30252957
7.

Impact of body weight, low energy diet and gastric bypass on drug bioavailability, cardiovascular risk factors and metabolic biomarkers: protocol for an open, non-randomised, three-armed single centre study (COCKTAIL).

Hjelmesæth J, Åsberg A, Andersson S, Sandbu R, Robertsen I, Johnson LK, Angeles PC, Hertel JK, Skovlund E, Heijer M, Ek AL, Krogstad V, Karlsen TI, Christensen H, Andersson TB, Karlsson C.

BMJ Open. 2018 May 29;8(5):e021878. doi: 10.1136/bmjopen-2018-021878.

8.

Determination of Tacrolimus Concentration and Protein Expression of P-Glycoprotein in Single Human Renal Core Biopsies.

Krogstad V, Vethe NT, Robertsen I, Hasvold G, Ose AD, Hermann M, Andersen AM, Chan J, Skauby M, Svensson MHS, Åsberg A, Christensen H.

Ther Drug Monit. 2018 Jun;40(3):292-300. doi: 10.1097/FTD.0000000000000510.

PMID:
29578937
9.
10.

The Authors' Reply.

Egeland EJ, Størset E, Robertsen I, Hermann M, Midtvedt K, Gustavsen MT, Klaasen R, Bergan S, Hartmann A, Åsberg A.

Transplantation. 2018 Jan;102(1):e43-e44. doi: 10.1097/TP.0000000000001961. No abstract available.

PMID:
28957846
11.

How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients.

Åsberg A, Robertsen I, Midtvedt K.

Transplantation. 2017 Nov;101(11):e347. doi: 10.1097/TP.0000000000001894. No abstract available.

PMID:
28787310
12.

High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation.

Egeland EJ, Robertsen I, Hermann M, Midtvedt K, Størset E, Gustavsen MT, Reisæter AV, Klaasen R, Bergan S, Holdaas H, Hartmann A, Åsberg A.

Transplantation. 2017 Aug;101(8):e273-e279. doi: 10.1097/TP.0000000000001796.

PMID:
28452920
13.

Closer to the Site of Action: Everolimus Concentrations in Peripheral Blood Mononuclear Cells Correlate Well With Whole Blood Concentrations.

Robertsen I, Vethe NT, Midtvedt K, Falck P, Christensen H, Åsberg A.

Ther Drug Monit. 2015 Oct;37(5):675-80. doi: 10.1097/FTD.0000000000000185.

PMID:
25565673
14.

Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed.

Robertsen I, Åsberg A, Ingerø AO, Vethe NT, Bremer S, Bergan S, Midtvedt K.

Transplantation. 2015 Mar;99(3):528-32. doi: 10.1097/TP.0000000000000384.

PMID:
25148382
15.

More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Robertsen I, Asberg A, Granseth T, Vethe NT, Akhlaghi F, Ghareeb M, Molden E, Reier-Nilsen M, Holdaas H, Midtvedt K.

Transplantation. 2014 Jun 27;97(12):1266-71. doi: 10.1097/01.TP.0000443225.66960.7e.

16.

Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients.

Robertsen I, Falck P, Andreassen AK, Næss NK, Lunder N, Christensen H, Gullestad L, Asberg A.

Transplant Res. 2013 Apr 8;2(1):5. doi: 10.1186/2047-1440-2-5.

17.

Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients.

Amundsen R, Asberg A, Robertsen I, Vethe NT, Bergan S, Hartmann A, Midtvedt K.

Transplantation. 2009 Apr 27;87(8):1221-4. doi: 10.1097/TP.0b013e31819f1001.

PMID:
19384170

Supplemental Content

Loading ...
Support Center